The impact of use serum carcinoembryonic antigen and beta 2-microglobulin in monitoring bronchogenic carcinoma therapy [electronic resource].

Includes references.

Bronchogenic carcinoma is a disease ofuncontrolled cell growth in tissues ofthe lung. This growth may lead to metastasis. Bronchogenic carcinoma, the most common cause of cancer-related death in men and the second most common in women (after breast cancer), it is responsible for 1.3 million deaths worldwide annually. The aim of this current study is to evaluate the prognostic properties and discriminative values of serum carcinoembryonic antigen (CEA) and beta2microglobulin (β2 M) in different stages of bronchogenic carcinoma. Its feasibility usage an easy and cheap marker especially in developing countries and their use instead an invasive biopsy to avoid its risk factors for improving the accuracy of diagnosing and screening of bronchogenic carcinoma. In addition, we aim to detect and monitor the response to the therapy. This prospective study performed on eighty patients with bronchogenic carcinoma before receiving any treatment.

1